{"id":"fludeoxyglucose-f18","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":"rare","effect":"Allergic reaction to radiopharmaceutical"},{"rate":"rare","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4297334","moleculeType":"Small molecule","molecularWeight":"441.40"},"_dailymed":{"setId":"1e415eb3-e8a5-4149-b4ec-ba9ab3b29d7f","title":"FLUDEOXYGLUCOSE F18 INJECTION [KREITCHMAN PET CENTER]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of fluorodeoxyglucose (FDG), a glucose molecule with a fluorine-18 radioisotope attached. Cancer cells and inflamed tissues consume glucose at higher rates than normal tissue, causing FDG to preferentially accumulate in these areas. The fluorine-18 emits positrons that are detected by PET scanners, producing detailed metabolic images to identify and localize disease.","oneSentence":"Fludeoxyglucose F18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling visualization via positron emission tomography (PET) imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:27.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma)"},{"name":"Cardiology: assessment of myocardial viability and perfusion"},{"name":"Neurology: evaluation of dementia and neurodegenerative disorders"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT02193425","phase":"EARLY_PHASE1","title":"Reliability of the Human Brain Connectome","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2015-06-08","conditions":"Normal Physiology","enrollment":112},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01934660","phase":"","title":"Links Between Inflammation and Cardiometabolic Diseases","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-12-02","conditions":"Diabetes Mellitus, Cardiovascular Disease, Healthy Volunteer","enrollment":150},{"nctId":"NCT06465017","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer","status":"TERMINATED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-01-04","conditions":"Tumor, Solid Tumor, Thyroid Cancer","enrollment":149},{"nctId":"NCT06503146","phase":"PHASE2","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-09","conditions":"Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma","enrollment":320},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":480},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT07494162","phase":"NA","title":"Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04","conditions":"Myofascial Pain Syndrome (MPS), Chronic Low-back Pain (cLBP)","enrollment":64},{"nctId":"NCT04943211","phase":"PHASE3","title":"Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":150},{"nctId":"NCT05756270","phase":"","title":"Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2022-06-03","conditions":"Mild Cognitive Impairment, Subjective Cognitive Decline","enrollment":150},{"nctId":"NCT03683355","phase":"","title":"Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-11-09","conditions":"Infective Endocarditis","enrollment":30},{"nctId":"NCT00006421","phase":"","title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-10-25","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04316117","phase":"PHASE2","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-09-15","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":138},{"nctId":"NCT07487883","phase":"","title":"Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-15","conditions":"Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules","enrollment":80},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT07479095","phase":"NA","title":"Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2025-07-03","conditions":"Lepidic-Predominant Lung Adenocarcinoma, Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT05191940","phase":"NA","title":"Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2022-05-16","conditions":"Pancreas Cancer","enrollment":30},{"nctId":"NCT07482072","phase":"","title":"Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03","conditions":"Alzheimer Dementia (AD), Diabete Type 2","enrollment":60},{"nctId":"NCT05931302","phase":"NA","title":"Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2023-11-16","conditions":"Lobular Breast Carcinoma","enrollment":40},{"nctId":"NCT04143516","phase":"PHASE2, PHASE3","title":"Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-10-25","conditions":"Liver Metastases","enrollment":200},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT06144853","phase":"","title":"The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2024-03-15","conditions":"Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis","enrollment":34},{"nctId":"NCT07471776","phase":"PHASE2","title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-03-11","conditions":"Metastatic Breast Cancer ( HER2 Negative)","enrollment":45},{"nctId":"NCT00194298","phase":"","title":"FDG-PET Imaging in Complicated Diabetic Foot","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2002-10","conditions":"Diabetic Foot Disease","enrollment":240},{"nctId":"NCT00194285","phase":"","title":"FDG-PET Imaging in Painful Joint Prosthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2001-03","conditions":"Painful Joint Prostheses","enrollment":530},{"nctId":"NCT04812080","phase":"NA","title":"EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-08-18","conditions":"Healthy Volunteers From Racial/Ethnic Minority Populations","enrollment":20},{"nctId":"NCT07463300","phase":"","title":"A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Lung Cancer","enrollment":5500},{"nctId":"NCT05876858","phase":"EARLY_PHASE1","title":"EXPLORER Total Body PET/CT Imaging for Myofascial Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2023-06-13","conditions":"Myofascial Pain","enrollment":53},{"nctId":"NCT05160480","phase":"","title":"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2024-06-07","conditions":"Prostate Cancer, Breast Cancer, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT04478318","phase":"NA","title":"Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2020-06-01","conditions":"Lung Neoplasm, Lymphoma, Melanoma","enrollment":180},{"nctId":"NCT04020978","phase":"NA","title":"Parametric PET of Genitourinary Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2019-07-16","conditions":"Genitourinary Cancer","enrollment":11},{"nctId":"NCT04841707","phase":"NA","title":"Total-Body Parametric 18F-FDG PET of COVID-19","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-05-10","conditions":"Covid19","enrollment":13},{"nctId":"NCT06014515","phase":"EARLY_PHASE1","title":"Single-tracer Multiparametric PET Imaging","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-02-14","conditions":"Healthy Subjects, Cardiovascular Disease","enrollment":60},{"nctId":"NCT02379377","phase":"PHASE1","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-15","conditions":"Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma","enrollment":110},{"nctId":"NCT07458906","phase":"NA","title":"DLL3-Targeted PET/CT in Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-12-01","conditions":"DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer","enrollment":60},{"nctId":"NCT04454450","phase":"NA","title":"Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-22","conditions":"Ovarian Cancer, High Grade Ovarian Serous","enrollment":10},{"nctId":"NCT07454096","phase":"PHASE4","title":"Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-04-30","conditions":"Cardiac Disease, Device Related Infection","enrollment":200},{"nctId":"NCT03853915","phase":"NA","title":"FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-23","conditions":"Cervical Cancer","enrollment":64},{"nctId":"NCT07442292","phase":"","title":"PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02","conditions":"Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer)","enrollment":40},{"nctId":"NCT07004673","phase":"","title":"18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-12","conditions":"Carotid Artery Plaque, Ischemic Stroke, PET / MR","enrollment":100},{"nctId":"NCT07448727","phase":"","title":"Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT","status":"RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2024-11-20","conditions":"Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT05321316","phase":"NA","title":"Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-05-31","conditions":"Urothelial Carcinoma","enrollment":20},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT07449858","phase":"","title":"18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-07-01","conditions":"Non Small Cell Lung Cancer","enrollment":500},{"nctId":"NCT05436093","phase":"NA","title":"CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-06-23","conditions":"Solid Tumor","enrollment":15},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT06502691","phase":"PHASE1, PHASE2","title":"[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-26","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":22},{"nctId":"NCT05710328","phase":"PHASE2","title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-05-10","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma","enrollment":235},{"nctId":"NCT07443696","phase":"PHASE2","title":"PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-12-18","conditions":"Ischemic Cardiomyopathy, Heart Failure","enrollment":40},{"nctId":"NCT04667585","phase":"NA","title":"Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx","status":"RECRUITING","sponsor":"Duke University","startDate":"2021-04-12","conditions":"Oropharynx Cancer","enrollment":120},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT06103838","phase":"PHASE2","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-25","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":60},{"nctId":"NCT02125786","phase":"PHASE2","title":"A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-07","conditions":"Ependymoma","enrollment":68},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07430475","phase":"","title":"Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2022-01-04","conditions":"Fever of Unknown Origin, Inflammation of Unknown Origin, Fever","enrollment":266},{"nctId":"NCT07431255","phase":"","title":"Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2026-03-01","conditions":"Alzheimer Disease (AD)","enrollment":35},{"nctId":"NCT07419867","phase":"PHASE2","title":"A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":"Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment","enrollment":850},{"nctId":"NCT05647564","phase":"NA","title":"PET/CT Characterization of Treatment Resistance","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":"Bone Metastases, HER2-positive Breast Cancer, Liver Metastases","enrollment":10},{"nctId":"NCT07285993","phase":"PHASE2","title":"Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET","status":"NOT_YET_RECRUITING","sponsor":"Randy Yeh","startDate":"2026-02-16","conditions":"Breast Cancer, Metastatic Invasive Lobular Breast Cancer","enrollment":15},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT04016818","phase":"EARLY_PHASE1","title":"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-06","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05775939","phase":"NA","title":"PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-20","conditions":"Lung Carcinoma, Esophageal Carcinoma","enrollment":20},{"nctId":"NCT05121012","phase":"","title":"Synaptic Loss in Multiple System Atrophy","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2021-09-01","conditions":"Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)","enrollment":36},{"nctId":"NCT04273555","phase":"PHASE1, PHASE2","title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-01","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT04359732","phase":"NA","title":"Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-05-08","conditions":"Esophageal Cancer, Esophageal Neoplasms","enrollment":121},{"nctId":"NCT01237054","phase":"PHASE2","title":"Imaging in MGUS, SMM and MM","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-17","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance","enrollment":31},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT04459273","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-27","conditions":"Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma","enrollment":26},{"nctId":"NCT07178587","phase":"NA","title":"Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-02","conditions":"Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)","enrollment":28},{"nctId":"NCT06083103","phase":"","title":"Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2023-10-12","conditions":"Cervical Cancer","enrollment":50},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT06836726","phase":"PHASE2","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-27","conditions":"Castration Resistant Prostate Cancer","enrollment":35},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":"Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":2},{"nctId":"NCT06225505","phase":"NA","title":"Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2026-01-05","conditions":"Triple Negative Breast Cancer","enrollment":450},{"nctId":"NCT04251481","phase":"NA","title":"Diffusion MRI for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-10-16","conditions":"Head Cancer Neck","enrollment":16},{"nctId":"NCT06297902","phase":"NA","title":"RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-08-19","conditions":"Head and Neck Cancer, Radiotherapy Side Effect","enrollment":100},{"nctId":"NCT03173924","phase":"PHASE2","title":"18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-06","conditions":"Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer","enrollment":96},{"nctId":"NCT03181867","phase":"PHASE2","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-03","conditions":"Prostate Neoplasms, Prostatic Cancer, Prostate Cancer","enrollment":800},{"nctId":"NCT06199713","phase":"","title":"Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-01-30","conditions":"Melanoma, Melanoma Stage III, Melanoma Stage IV","enrollment":24},{"nctId":"NCT07353554","phase":"NA","title":"Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":"Multiple Myeloma (MM)","enrollment":30},{"nctId":"NCT07313033","phase":"NA","title":"[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-03-30","conditions":"Lobular Carcinoma, Breast Cancer","enrollment":45},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":"B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":18},{"nctId":"NCT04333537","phase":"PHASE2, PHASE3","title":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2020-09-23","conditions":"Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma","enrollment":686}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20200624","type":"SUPPL","sponsor":"3D IMAGING DRUG","applicationNumber":"ANDA203778"},{"date":"20151030","type":"ORIG","sponsor":"3D IMAGING DRUG","applicationNumber":"ANDA203778"},{"date":"20150717","type":"ORIG","sponsor":"UNIV MICHIGAN","applicationNumber":"ANDA204531"},{"date":"20150501","type":"ORIG","sponsor":"BIOMEDCL RES FDN","applicationNumber":"ANDA203837"},{"date":"20210122","type":"SUPPL","sponsor":"BIOMEDCL RES FDN","applicationNumber":"ANDA203837"},{"date":"20140509","type":"ORIG","sponsor":"UCSF RODIOPHARM","applicationNumber":"ANDA203902"},{"date":"20210304","type":"SUPPL","sponsor":"UCSF RODIOPHARM","applicationNumber":"ANDA203902"},{"date":"20150423","type":"ORIG","sponsor":"METHODIST HOSP RES","applicationNumber":"ANDA203904"}],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"Fludeoxyglucose F18","genericName":"Fludeoxyglucose F18","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludeoxyglucose F18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling visualization via positron emission tomography (PET) imaging. Used for Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma), Cardiology: assessment of myocardial viability and perfusion, Neurology: evaluation of dementia and neurodegenerative disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}